Skip to content

Protagonist Therapeutics

US · PTGX #1570 by market cap Listed 2016
121.40 -2.62 -2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 30 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.0 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
122.42% +1.97pp
Institutions
460 +30
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund82.73%
Hedge Fund25.61%
VC/PE Fund5.85%
Public Company4.86%
Private Company1.35%
Government Pension Fund1.16%
Individual/Insider0.59%
Family Office/Trust0.42%
Insurance Company0.39%

Top holders as of 2026-09-30

BlackRock 15.07% · 9.83M sh
Farallon Capital Management, L.L.C. 9.73% · 6.35M sh
RTW Investments, LP 7.75% · 5.06M sh
UBS Asset Management 6.22% · 4.06M sh
Vanguard Portfolio Management, LLC 5.62% · 3.67M sh
State Street Global Advisors 5.33% · 3.48M sh
Wellington Management Group 5.23% · 3.42M sh
Vanguard Capital Management, LLC 4.44% · 2.90M sh
Johnson & Johnson Innovation - JJDC, Inc. 3.75% · 2.45M sh
T. Rowe Price Group, Inc. 3.29% · 2.15M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 17 buys · 33 sells

NameRoleStake
Dinesh Patel CEO, President, Secretary & Director 0.44%
Harold Selick Independent Chairperson 0.09%
Arturo Molina Chief Medical Officer 0.02%
Bryan Giraudo Independent Director 0.02%
Sarah O’Dowd Independent Director 0.01%
Lewis Williams Independent Director 0.01%
William Waddill Independent Director 0.01%
Asif Ali Chief Financial Officer 0.00%
Suneel Gupta Former Executive Vice President of Clinical Development --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-29 Asif Ali Chief Financial Officer Derivative Exercise and Sale -58,629 $12.17–141.78
2026-09-09 Dinesh Patel CEO, President, Secretary & Director Derivative Exercise and Sale -125,000 $21.58–146.18
2026-09-02 Dinesh Patel CEO, President, Secretary & Director Other Disposition -510 --
2026-08-10 Dinesh Patel CEO, President, Secretary & Director Derivative Exercise and Sale -100,000 $21.58–149.11
2026-06-22 William Waddill Independent Director Derivative Exercise and Sale -9,000 $16.54–117.94
2026-06-09 William Waddill Independent Director Derivative Exercise and Sale -9,000 $11.80–107.68
2026-05-28 William Waddill Independent Director Derivative Exercise and Sale -9,000 $11.80–99.64
2026-05-11 Dinesh Patel CEO, President, Secretary & Director Derivative Exercise and Sale -75,000 $21.58–100.12
2026-05-07 Bryan Giraudo Independent Director Open Market Disposition -23,130 $100.00–100.07
2026-05-06 Bryan Giraudo Independent Director Derivative Exercise and Sale -36,000 $6.45–100.14
2026-04-22 Dinesh Patel CEO, President, Secretary & Director Other Disposition -1,460 --
2026-04-19 Asif Ali Chief Financial Officer Open Market Disposition -1,750 $105.47
2026-03-25 Harold Selick Independent Chairperson Derivative Exercise and Sale -24,000 $12.88–105.00
2026-03-25 Arturo Molina Chief Medical Officer Derivative Exercise and Sale -15,000 $8.04–104.79
2026-03-25 Asif Ali Chief Financial Officer Derivative Exercise and Sale -24,765 $12.17–104.24
2026-03-24 Dinesh Patel CEO, President, Secretary & Director Derivative Exercise and Sale -54,700 $8.58–101.00
2026-03-22 Dinesh Patel CEO, President, Secretary & Director Other Disposition -50,000 --
2026-02-16 Lewis Williams Independent Director Derivative Exercise and Sale -18,000 $10.84–82.42
2026-02-05 William Waddill Independent Director Derivative Exercise and Sale -20,000 $8.31–83.68
2026-01-26 Dinesh Patel CEO, President, Secretary & Director Derivative Exercise and Sale -48,273 $4.21–84.59

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Protagonist Therapeutics discussion 0 comments

Add a comment